Eli Lilly's (LLY) jaypirca significantly continued progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
Importance
Level 1
- BRUIN CLL-322 is the first Phase 3 readout in CLL to utilize and outperform a venetoclax-containing control arm.